Literature DB >> 17964418

Redox-dependent impairment of vascular function in sickle cell disease.

Mutay Aslan1, Bruce A Freeman.   

Abstract

The vascular pathophysiology of sickle cell disease (SCD) is influenced by many factors, including adhesiveness of red and white blood cells to endothelium, increased coagulation, and homeostatic perturbation. The vascular endothelium is central to disease pathogenesis because it displays adhesion molecules for blood cells, balances procoagulant and anticoagulant properties of the vessel wall, and regulates vascular homeostasis by synthesizing vasoconstricting and vasodilating substances. The occurrence of intermittent vascular occlusion in SCD leads to reperfusion injury associated with granulocyte accumulation and enhanced production of reactive oxygen species. The participation of nitric oxide (NO) in oxidative reactions causes a reduction in NO bioavailability and contributes to vascular dysfunction in SCD. Therapeutic strategies designed to counteract endothelial, inflammatory, and oxidative abnormalities may reduce the frequency of hospitalization and blood transfusion, the incidence of pain, and the occurrence of acute chest syndrome and pulmonary hypertension in patients with SCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964418      PMCID: PMC2139908          DOI: 10.1016/j.freeradbiomed.2007.08.014

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  180 in total

Review 1.  Reactive species in sickle cell disease.

Authors:  M Aslan; D Thornley-Brown; B A Freeman
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 2.  Erythroid cell adhesion molecules Lutheran and LW in health and disease.

Authors:  S F Parsons; F A Spring; J A Chasis; D J Anstee
Journal:  Baillieres Best Pract Res Clin Haematol       Date:  1999-12

3.  Fatal sickle cell crisis after granulocyte colony-stimulating factor administration.

Authors:  B K Adler; D E Salzman; M H Carabasi; W P Vaughan; V V Reddy; J T Prchal
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

Review 4.  Regulation of blood coagulation.

Authors:  C T Esmon
Journal:  Biochim Biophys Acta       Date:  2000-03-07

5.  Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells.

Authors:  R D Smith; J Li; C T Noguchi; A N Schechter
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

6.  Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor.

Authors:  D K Kaul; H M Tsai; X D Liu; M T Nakada; R L Nagel; B S Coller
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

Review 7.  NF-kappaB activation.

Authors:  E Abraham
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

8.  Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent.

Authors:  K J Sullivan; S R Goodwin; J Evangelist; R D Moore; P Mehta
Journal:  Crit Care Med       Date:  1999-11       Impact factor: 7.598

9.  Reperfusion injury pathophysiology in sickle transgenic mice.

Authors:  U R Osarogiagbon; S Choong; J D Belcher; G M Vercellotti; M S Paller; R P Hebbel
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

10.  Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals.

Authors:  D A Parks; D N Granger
Journal:  Am J Physiol       Date:  1983-08
View more
  28 in total

1.  Lipoprotein subfraction profile and HDL-associated enzymes in sickle cell disease patients.

Authors:  Oktay H Ozturk; Yesim Can; Zafer Yonden; Sedat Motor; Gonul Oktay; Hasan Kaya; Mutay Aslan
Journal:  Lipids       Date:  2013-10-11       Impact factor: 1.880

Review 2.  Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.

Authors:  Angela Rivers; Ramasamy Jagadeeswaran; Donald Lavelle
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-08-01       Impact factor: 3.619

Review 3.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

Review 4.  The multifaceted role of ischemia/reperfusion in sickle cell anemia.

Authors:  Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 5.  Antibiotics for treating osteomyelitis in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

6.  LC-MS/MS analysis of plasma polyunsaturated fatty acids in patients with homozygous sickle cell disease.

Authors:  Mutay Aslan; Gamze Celmeli; Filiz Özcan; Alphan Kupesiz
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 3.984

7.  Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia.

Authors:  Chun-Seok Cho; Gregory J Kato; Seung Ha Yang; Sung Won Bae; Jong Seo Lee; Mark T Gladwin; Sue Goo Rhee
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

Review 8.  Heme degradation and vascular injury.

Authors:  John D Belcher; Joan D Beckman; Gyorgy Balla; Jozsef Balla; Gregory Vercellotti
Journal:  Antioxid Redox Signal       Date:  2010-02       Impact factor: 8.401

9.  Vascular dysfunction in a murine model of severe hemolysis.

Authors:  Anne C Frei; YiHe Guo; Deron W Jones; Kirkwood A Pritchard; Karen A Fagan; Neil Hogg; Nancy J Wandersee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

10.  A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis.

Authors:  Robert P Hebbel; Greg Vercellotti; Karl A Nath
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.